Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation

T Brown,1 G Pilkington,1 A Bagust,1 A Boland,1 J Oyee,1 C Tudur Smith,2 M Blundell,1 M Lai,1 C Martin Saborido,1 J Greenhalgh,1 Y Dundar1 and R Dickson1*

1Liverpool Reviews and Implementation Group (LRiG), Institute of Psychology, Health and Society, Department of Health Services Research, University of Liverpool, Liverpool, UK
2Department of Biostatistics, University of Liverpool, Liverpool, UK

*Corresponding author

Corrigendum issued May 2015
Corrigendum DOI: 10.3310/hta17310-c201505
Original DOI: 10.3310/hta17310

The original report should be referenced as follows:


Health Technology Assessment is indexed and abstracted in Index Medicus/ MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine.
Corrigendum notice

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation

T Brown, G Pilkington, A Bagust, A Boland, J Oyee, C Tudur Smith, M Blundell, M Lai, C Martin Saborido, J Greenhalgh, Y Dundar and R Dickson

This paper1 is corrected as follows:

Appendix 22: Table 96 is replaced with the following text:

Table 96 has been removed as it includes incorrect hazard ratios caused by a reversal of the hazard ratio calculations. However, this does not impact on any of the clinical or economic results reported.

Chapter 3, under the heading ‘Survival risk at year 1 and year 2 post randomisation’: The following text is removed:

Analyses for 1-year survival show no evidence to suggest any difference in survival between the third-generation chemotherapy treatments except for PEM + PLAT compared with GEM + PLAT that demonstrated significant evidence of 1-year survival advantage for PEM over GEM.

Reference